Antihyperglycemic effect of a caffeamide derivative, KS370G, in normal and diabetic mice.
The antihyperglycemic actions of caffeamide derivatives, especially KS370G, in normal ICR, streptozotocin-induced diabetic (T1DM) and diet-induced diabetic (T2DM) mice were investigated in this study. Oral administration of the compound decreased the plasma glucose levels in both normal and diabetic mice, and appeared to be in a dose-dependent manner in normal and diet-induced type 2 diabetic mice. It was found that KS370G could stimulate the release of insulin in both normal and T2DM mice, and a dose of 1 mg per kg KS370G could significantly attenuate the increase of plasma glucose induced by an intraperitoneal glucose challenge test in normal and diabetic mice. Similar treatment with KS370G significantly increased glycogen content in both liver and skeletal muscle. Hence, the hypoglycemic effect of KS370G in normal and diabetic mice could be attributed to the stimulation of insulin release and the increase of glucose utilization.
Weng
Yi-Chun
YC
Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Chiu
Hsi-Lin
HL
Lin
Yen-Chu
YC
Chi
Tzong-Cherng
TC
Kuo
Yueh-Hsiung
YH
Su
Ming-Jai
MJ
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002109:Caffeic Acids / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D007004:Hypoglycemic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR
D001786:Blood Glucose; D002109:Caffeic Acids; D007004:Hypoglycemic Agents; D007328:Insulin; C554967:KS370G